Recent News

• 03.05.2025 - Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
• 03.04.2025 - Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
• 01.23.2025 - Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
• 11.12.2024 - Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
• 11.04.2024 - Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
• 10.25.2024 - Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
• 10.03.2024 - Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
• 09.09.2024 - Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
• 09.04.2024 - Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Recent Filings

• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.05.2025 - 8-K Current report
• 02.05.2025 - EX-99.1 EX-99.1
• 11.29.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors
• 11.12.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2024 - 8-K Current report
• 11.12.2024 - EX-99.1 EX-99.1
• 11.04.2024 - EX-99.1 EX-99.1
• 11.04.2024 - 8-K Current report